



**HAL**  
open science

## Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study

Yassine Eid, Véronique Bouvier, Benjamin Menahem, Alexandre Thobie, Nathan Dolet, Morgane Finochi, Marine Renier, Joséphine Gardy, Guy Launoy, Olivier Dejardin, et al.

### ► To cite this version:

Yassine Eid, Véronique Bouvier, Benjamin Menahem, Alexandre Thobie, Nathan Dolet, et al.. Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study. *Surgery*, 2019, 166, pp.327 - 335. 10.1016/j.surg.2019.04.007 . hal-03488165

**HAL Id: hal-03488165**

**<https://hal.science/hal-03488165>**

Submitted on 20 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

# Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: outcome of a high-resolution population-based study

Yassine Eid<sup>1, 2, 3</sup>, Véronique Bouvier<sup>2,4</sup>, Benjamin Menahem<sup>1, 2, 3</sup>, Alexandre Thobie<sup>1, 2, 3</sup>, Nathan Dolet<sup>2, 3</sup>, Morgane Finochi<sup>1, 3</sup>, Marine Renier<sup>2</sup>, Joséphine Gardy<sup>2, 4</sup>, Guy Launoy<sup>2,3,4</sup>, Dejardin O<sup>2,3</sup>, Rémy Morello<sup>3, 5</sup>, Arnaud Alves<sup>1, 2, 3</sup> and Rectqol Group.

<sup>1</sup> Department of digestive surgery, University Hospital of Caen, Avenue de la Côte de Nacre, 14032, Caen Cedex, France.

<sup>2</sup> ANTICIPE" U1086 INSERM-University of Caen Normandy, Team « Ligue contre le Cancer », Centre François Baclesse, Caen, France

<sup>3</sup> Department of research, University Hospital of Caen, Normandy, France

<sup>4</sup> University Hospital of Caen, Caen cedex, France; Digestive Cancer Registry of Calvados

<sup>5</sup> Department of biostatistics and clinical research, University Hospital of Caen, 14000 Caen cedex, France

**Corresponding author:** Dr Yassine EID, Department of Digestive Surgery, University Hospital of Caen, Avenue de la Côte de Nacre, 14000 Caen cedex, France. Email: [eidyassine@hotmail.fr](mailto:eidyassine@hotmail.fr) Tel: 0231063221 Fax: 0231064468.

**Rectqol Group:** Dr Amar Abdelli, Dr Marie-Vincent Ahkong, Dr Barbara Alkofer, Dr Bernard Apoil, Dr Louis Paul Argouarch, Dr Philippe Armand, Dr Dominique Arsène, Dr Sylvain Auvray, Dr Richard Barthélémy, Dr Céline Bazille, Dr Anne Laure Bignon, Dr Cécile Bonnamy, Dr Karine Bouhier-Leporrier, Dr Eric Borotto, Dr Jean-Louis Brefort, Dr Jaroslaw Chomontovski, Dr Daniel Cohen, Dr Michel Cojocar, Dr Thierry Collet, Dr Patrick Congard, Dr Stéphane Corbinais, Dr Marc Couque, Dr Eric Degoutte, Dr Jean-Pierre Desfachelles, Dr Benoit Dupont, Dr Samouh Elfadél, Dr Marie-Pierre Galais, Dr Frédéric Genuist, Dr Nicolas Girard, Dr Romain Gloro, Dr Antoine Granveau, Dr Jean-Marc Guilloit, Dr Sophie Hervé, Dr Mehdi Hessissen, Dr Jacques Jacob, Dr Eric Kalinski, Dr Demetrios Koutsomanis, Dr Laurent Lagriffoul, Dr Christelle Lartigau, Dr Laurent Lechevallier, Dr Gil Lebreton, Dr Anne-Charlotte Lefebvre, Dr Denis Lefrançois, Dr Claudine Lepoittevin, Dr Julien Leporrier, Dr Yannick Le Roux, Dr André L'Hirondel, Dr Christian L'Hirondel, Dr Laurent Lion, Dr Ammar Makki, Dr Patrice Marchand, Dr Yoann Marion, Dr Denis Mauger, Dr Laurent Mosquet, Dr Denis No Mura, Dr Jean Michel Ollivier, Dr Aurélie Parzy, Dr Emmanuel Polycarpe, Dr Florence Polycarpe, Dr Didier Reijasse, Dr Catherine Renet, Dr Cyprien Rodriguez, Dr Lakhdar Saadi, Pr Guy Samama, Dr Mihaela Saplacan, Dr Farouk Sleman, Dr Franck Siriser, Dr Jacques Soufron, Dr Yves Teste, Dr Laurent-Eric Tiengou, Dr Jean-Pierre Toudic

## **Abstract**

**Background:** With the rising number of rectal cancer (RC) survivors, more patients with sphincter-preserving surgery (SPS) are having to live with a potentially impaired quality of life (QoL). The survey aimed to assess bowel and genitourinary sequelae and their impact on QoL in an unselected registry-based population of RC survivors.

**Methods:** This cross-sectional cohort survey (registered at ClinicalTrials.gov (ID: NCT03459235) included RC patients who underwent curative surgery with SSP from 01/01/2007 to 01/31/2015. Patients with recurrent disease, intestinal stoma or cognitive disorders were excluded. Validated scoring system included: Urinary Symptom Profile in women and International Prostate Symptom Score in men for urinary function, International Index for Erectile Function 5 in men and Female Sexual Function Index in women for sexual function, QLQ-C30/CR29 questionnaires for QoL and Low Anterior Resection Syndrome (LARS) score for bowel function. The impact of functional sequelae on global QoL was evaluated by multiple linear regression.

**Results:** Responders (45.3% of the 203 patients) and non-responders were comparable according to sex, age, tumor stage and neoadjuvant chemoradiation. With a mean follow-up of 6.5 years, 65.2% of the RC survivors suffered from bowel dysfunction, of whom 41.3% experienced major LARS, and 80% of RC survivors experienced genitourinary dysfunction. In multiple linear regression, poor bowel function was a significant predictor of global QoL in men ( $P=0.04$ ) and women ( $P=0.0003$ ).

**Conclusion:** This survey highlights the importance of sexual and bowel dysfunction in RC survivors and the strong correlation between high LARS score and inferior QoL. Further studies are needed to improve knowledge on how to predict bowel dysfunction and how to best support patients with bowel dysfunction.

**Key words:** Rectal cancer, Sphincter-saving procedures, Quality of life, Validated scoring system

## Introduction

In recent years, progress in the multimodal treatments of rectal cancer (RC) has improved local disease control and increased the survival rate (up to 50% survival at 5 years) (1,2). At the same time, the evolution of surgical techniques and the achievement of a 1-cm distal margin below the tumor have pushed back the limits of sphincter-preserving surgery (SPS) without impairing oncological prognosis (3,4). Assessment of RC outcome has traditionally focused on morbidity rate, tumor recurrence and survival, while functional sequelae (ie, bowel and/or genitourinary) have long been regarded as inherent to the nature of oncologic treatments (5). However, with improved oncologic outcomes, we and others have observed a rising number of RC survivors who live with numerous potential side-effects and an eventually impaired quality of life (QoL) (6–9). Therefore, QoL has become an increasingly important focus of care (10).

Most patients will experience significant side-effects of RC treatment (6,7). After low anterior resection with SPS, it is widely accepted up 50% to 90% of patients will experience a change in bowel habit (6, 11, 12) that is termed “low anterior resection syndrome” (LARS). LARS can severely impact QoL (13). However, the ways in which bowel dysfunction is measured and reported vary considerably (14), so estimates of adverse events may be unreliable. First used in Denmark in 2012, the “LARS score” is to date the best questionnaire for capturing postoperative bowel function amongst a number of instruments (15,16). Furthermore, there may be considerable discrepancy between the clinician’s judgement of patient perception and the patient’s actual belief or experience (17).

Furthermore, genitourinary problems are common, multifactorial and inadequately explored (7). De novo urinary sequelae (in nearly 33% of patients) may occur after RC surgery, including de novo urinary incontinence in one-third of patients and voiding dysfunction in one-fourth (7). Likewise, sexual sequelae occur in three-quarters of men (erectile and ejaculation dysfunction) and in two-thirds of women (dyspareunia or vaginal shrinkage), leading to de novo loss of sexual activity in 28% of men and 18% of women (7). However, most studies are retrospective, have small samples, short-term follow-up, and use non-validated instruments (7,18).

In addition, considerable variations in information provision regarding the pros and cons of treatments have been reported (19). RC patients receive insufficient information regarding the potential side-effects of treatment (19), yet they need precise details about the risk of developing such disturbances. Although recent studies have focused on various issues such as bowel and genitourinary function and health-related QoL (8,20), very few studies to our knowledge have provided clinicians with a complete picture of overall functions (21,22). Furthermore, there is little consensus regarding the use of specific instruments or validated scores (6,7). This study therefore used well-validated instruments to assess functional outcomes in a holistic manner in an unselected general population of RC survivors. In addition, we investigated whether there is a strong relation between functional outcome and impaired QoL.

## **Methods**

This study was carried out according to the terms of the Declaration of Helsinki, approved by the local ethics committee (ID-RCB: 2017-A02645-48) and registered at ClinicalTrials.gov (ID: NCT03459235).

### *Design and participants*

In this cross-sectional population-based study, patients eligible for inclusion were identified by the digestive cancer registry of Calvados, which records all incident cases in Calvados, a French department located in Northwest of France. The population of Calvados was estimated at 694,660 people in 2016. Unlike a general cancer registry, a digestive cancer registry records high-resolution data on all diagnosed digestive cancers (updated follow-up, high-resolution data on treatment, detailed surgical data, adjuvant therapy and ongoing monitoring). Data quality and completeness of the registry were assessed by the CER (Registries Evaluation Committee) and by the International Agency for Research on Cancer (IARC). The database has been declared to the National Commission on Information Technology and Civil Liberties (CNIL, n°998018).

Data from all patients with a rectal adenocarcinoma diagnosed in Calvados between 01/01/2007 and 31/01/2015 (C20, 8140/3 in International Classification of Diseases for Oncology 3) were extracted (N=

931) (Figure 1). Inclusion criteria were: age above 18 years and under 80 years at inclusion, curative total or partial mesorectal excision (TME or PME) for RC since 2007. Each RC was located between 0 and 15 cm from the anal verge. Low RC were defined as a tumor  $\leq 6$  cm from the anal verge. PME was performed on selected upper rectal tumors that mobilized sufficiently for the mesorectum to be transected at least 5cm below the tumor (4). The exclusion criteria were: no resection or palliative cancer resection, the presence of known disseminated or recurrent disease, intestinal stoma or patients whose bowel continuity had been restored for less than 24 months. Mental dementia, cognitive disorders and/or the inability to read and understand the French language were also exclusion criteria.

Finally, 402 patients were eligible for crosschecking data with paper or computerized medical files (figure 1). Medical data were updated and patients with exclusion criteria or who had died were excluded. Consequently, survivors were defined as follows: alive patients assessed for eligibility on 02/01/2018 (n=255 – figure1). Additional information regarding mental state, linguistic abilities and postal addresses was obtained by checking medical records. Thus, 52 alive patients were excluded due to local or distant recurrence and redo surgery for stoma. Consequently, 203 letters containing the questionnaires were sent and 150 dunning letters were re-sent (in the event of no response after 30 days). Patients who left their phone number on the questionnaire were reminded in the event of missing answers. Patients who had not responded to the questionnaires after three months were considered as non-responders.

### *Questionnaires*

Seven validated questionnaires were used.

QoL was evaluated with the generic European Organization for Treatment and Research of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) (23) and the specific colorectal module (EORTC QLQ-CR29) (24). The scores were summed and converted to a 0 to 100 scale according to the EORTC scoring manual. (25)

Bowel function assessment included a translated French version of the LARS score to evaluate digestive sequelae (thanks to the agreement of Therese Juul)(26). The French version of the LARS score is currently being validated and supported by the French Research Group for Rectal Cancer Surgery (GRECCAR). The LARS score is a patient-reported outcome measure to evaluate the severity of bowel dysfunction after rectal surgery by scoring the five major symptoms of LARS (15): incontinence (flatus and liquid stool), frequent bowel movements, fragmentation/clustering of stools, and urge. The score ranges from 0 to 42 and defined no LARS (LARS score from 0 to 20), minor LARS (score from 21 to 29) and major LARS (score from 30 to 42). (15)

To evaluate urinary function in men, we used the International Prostate Symptom Score (IPSS), which is a structured and validated self-questionnaire evaluating lower urinary dysfunction (7). The IPSS questionnaire includes a QoL assessment according to urinary symptoms from 0 (best) to 6 (worst). It is based on seven items (incomplete bladder emptying, micturition frequency, intermittent micturition, urgency, strength of the stream, straining and nocturia) during the preceding four weeks. Each item is scored from 0 (best) to 5 (worst). Urinary function was graded in three subgroups: normal function (0-7 points), moderate dysfunction (8-19 points), and severe dysfunction (20-35 points).

In women, we used the Urinary Symptom Profile (USP), which is a self-report instrument including a 13-item questionnaire developed and validated in French by Haab et al (27). The instrument explores three dimensions: stress urinary incontinence, overactive bladder, and urinary obstruction symptoms. Dimensions 1 and 3 are scored from 0 to 9, and dimension 2 is scored from 0 to 21. A score of 0 represents absence of symptoms and 9 or 21 maximal severity symptoms. The USP has no cutoff score.

Male sexual function was assessed by the International Index of Erectile Function questionnaire (IIEF 5) which is composed of five questions divided into five domains: erection, orgasm, desire, satisfaction with sexual intercourse and overall satisfaction (7). The answers to each question indicate the experience of the patient during the preceding four weeks on a 5-point Likert scale. The IIEF-5 score was calculated by adding

the score for each item and ranged from 5 to 25. Erectile function in patients with sexual inactivity (0-4 points) was not analyzed. A total score equal to or greater than 21 was considered “normal”.

In women, we used the Female Sexual Function Index (FSFI), which is the most widely used scale consisting in 19 items and evaluating female sexual dysfunction. The index consists of six individual domains: desire, excitation, lubrication, orgasm, satisfaction and pain. Each title is scored between 0/1 and 5 points. The lowest score is 2 and the highest score is 36. A high score indicates better function. According to the authors, functional condition is good if FSFI score is > 30, moderate if between 23-29, and poor if < 23. A score under 26.55 was classified as Female Sexual Disorder (FSD) (28).

### *Statistical analysis*

T tests were used to assess score differences between groups. Statistical significance was accepted at the P value  $\leq 0.05$  level. Clinical significance of the score differences on each scale was determined using a validated minimal clinically important difference study of the EORTC questionnaire. The questionnaires EORTC QLQ-C30 and QLQ-CR29 were scored according to the methods recommended by the developers. Missing data were handled as instructed in the scoring manuals. For the other questionnaires, missing data were handled in complete case analysis. Data are presented in univariate analysis according to the predictive factors known to affect or impair functional outcomes (sex, age at surgery, neoadjuvant radiation therapy, extent of mesorectal excision PME or TME and the kind of colorectal anastomosis (straight versus colonic reservoir). Linear regression and multiple linear regression (with backward selection) were performed in order to analyze the impact of the functional sequelae on global QoL. Statistical analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA).

## **Results**

Two hundred and three patients were included in the study (questionnaires sent). In summary, 92 patients (45.3% of included patients) returned the questionnaires and were considered as responders. The other



111 patients (54.7%) were considered as non-responders (Figure 1). The average response time was 24.3 days (SD 17.3 days) ranging from 5 to 78 days. The completeness level of the various questionnaires was at least 94% except for the subscale “satisfaction” of the FSFI among women (28.6% missing answers).

### *Patient demographics*

Both groups (responders and non-responders) were comparable according to age, sex, tumor stage, neoadjuvant and adjuvant therapy, surgical approach, type of rectal resection, and type of intestinal reconstruction (i.e., colon-J-pouch or side-to-end versus straight colorectal anastomosis).

The mean follow-up from the operation to the time of questionnaire completion for the responders was 6.5 years (range 3.01 – 10.86 years, Table 1). The mean age of responders at the time of operation was 60.7 years (range 29.2 – 76.1 years) and 64 were males (69.6%). Most RC were located in the low and mid rectum (66.3%). Half of the responders underwent neoadjuvant radiotherapy and 59 (64.1%) did not have any adjuvant treatment. The most frequent surgical approach was the open approach (67.4%), followed by laparoscopy (23.9%) and by conversion to open surgery (7.6%). Colonic reservoir was the procedure in 66 responders (61.0%) and a temporary ostomy was performed in 53 patients (57.6%).

### *Health-related QoL and Functional Outcomes*

#### *Bowel function*

Median LARS score in responders was 27 and the mean was 24.2 (SD 12.5) ranging from 0 to 39.

Almost two-thirds (65.2%) of the population had a LARS (score>20), including 41.3% with a major LARS. Data were missing for one of the 92 patients of the survey, as shown in Table 2. Neoadjuvant radiation therapy (P<0.001) and TME (P=0.006) were significantly associated with the severity of LARS score.

#### *Urinary function*

In men, median IPSS score in responders was 5 and the mean was 6.0 (SD 5.4), ranging from 0 to 28. Most patients (98.4%) had mild or moderate dysfunction. Data were missing for two of the 64 male patients

(Table 3.A). In women, median USP score in responders was 4 and the mean 5.0 (SD 4.6), ranging from 0 to 19. The three dimensions explored by the USP score are shown in Table 3.B. There was no missing data. For both men and women, IPSS category and USP scores were independent of neoadjuvant radiation therapy, extent of mesorectal excision and type of colorectal anastomosis.

### *Sexual function*

In men, median IIEF score was 7 and the mean was 8.75 (SD 7.8). Only six men (9.4%) did not suffer from erectile dysfunction (table 4.A) and severe erectile dysfunction was observed in 59.3% of men. In women, median FSFI score was 5.7 and the mean was 12.4 (SD 12.0). Only 6 women (21.4%) did not have an FSD (defined as a total FSFI score above 26.55). Data were missing for 4 women (14%) on the desire and arousal domains and for 8 women (29%) on the satisfaction domain (Table 4.B). For both men and women, IIEF5 categories and FSFI domains were independent of neoadjuvant radiation therapy, extent of mesorectal excision and type of colorectal anastomosis.

### *Health-related Quality of Life (HRQOL)*

Results of the EORTC QLQ-C30 and CR29 are shown in Tables 6 and 7 (supplementary material). The global QoL score was similar among men and women, as were role, emotional, cognitive and social functions. In univariate analysis of the QLQ C-30, worse social functioning was significantly associated with TME (77.8 vs 92.2 P=0.008) and use of neoadjuvant radiation therapy (77.4 vs 87.8 P=0.04). Neoadjuvant radiation therapy was significantly associated with worse diarrhea (34.0 vs 18.8, P=0.01). Otherwise, no significant differences were found. When CR29 was considered, patient's body image perception was significantly worse after neoadjuvant radiation therapy (P=0.003) and TME (P=0.02). Fecal incontinence was significantly worsened by TME (P=0.008) and neoadjuvant radiation therapy (P=0.001). Furthermore, neoadjuvant radiation therapy was significantly associated with increased stool frequency (P<0.001), buttock pain (P=0.04), flatulence (P=0.001), sore skin (P=0.001) and embarrassment (P=0.001). Men appeared to have more blood and mucus in stools than women (P=0.05).

## *Multiple Linear regression*

In univariate analysis, urinary function and bowel function were significantly associated to QoL for men and the bowel function was the only predictor of QoL for women. In multiple linear regression using a backward selection, poor bowel function impaired global QoL significantly in men (coefficient estimate at -0.39 with P=0.04) and in women (-1.22 with P=0.0003), as shown in Table 5. In women, age was associated with QoL (coefficient estimate at 0.57 with P=0.03).

## **Discussion**

The results of this survey highlight the notable functional consequences reported by RC survivors after SPS. Based on validated instruments, 40% of RC survivors suffered from a major LARS that significantly impaired their quality of life. More interestingly, bowel dysfunction was the only predictor of QoL for such patients, after adjustment on age and different parts of QoL (urinary and sexual function).

Although numerous studies have explored the impact of RC treatments on QoL (10), they have often been limited by the duration of follow-up. However, a large proportion of the increasing number of RC survivors have to date been living more than 5 years after treatment. In contrast to many studies including RC survivors (10), we used specific validated questionnaires for both bowel and genitourinary functions. In our study, 40% of RC survivors experienced major LARS. Three studies have previously used the LARS score to evaluate bowel function in RC survivors with a long-term follow-up. Bregendahl et al found that 41% of patients experienced major LARS after a median of 54 months (29). Based on the outcome of a randomized multicenter trial, Chen et al reported that 46% of patients suffered from major LARS at 14 years (30). Consistent with previous studies, we found a strong relationship between neoadjuvant radiation therapy and major LARS, and between TME and major LARS (6,29,30).

We also found a strong association in multivariable analysis between severe bowel dysfunction and QoL, especially regarding global health status. Our study is not the first to demonstrate an association between LARS score and QoL (31), but it is the first to evaluate all functional sequelae (bowel and genito-urinary)

and QoL (global and specific) at the same time and in a high-resolution population-based study (32). This strong association is even more important in that the prevalence of major LARS does not change over time (33). QoL was significantly impaired by severe bowel dysfunction (LARS score  $\geq$  30) instead of sexual or urinary dysfunction, based on the seven validated questionnaires used. Consequently, it will be relevant to predict early bowel dysfunction severity, based on predictive factors identified in the literature, such as the POLARS score (34). Furthermore, this individualized strategy may help us to guide our treatment decision, by avoiding neoadjuvant radiotherapy in high rectal lesions or in middle rectal lesions staged T3a/b (35) or by performing abdominoperineal excision with permanent stoma instead of sphincter-sparing surgery with intersphincteric resection in older patients who have ultralow rectal lesions. However, the POLARS score has not been validated in a French population, and there are several important factors that it does not control, such as socioeconomic status and comorbidities. We have recently reported that the prevalence of sphincter-sparing surgery might be influenced by socioeconomic deprivation (36). Additionally, better preoperative patient education and counselling might reduce symptoms and improve QoL (37,38). A detailed algorithm has been suggested for managing anterior resection syndrome based on a review of the literature (6).

An alternative strategy for high-risk patients is the “watch-and-wait” policy, which causes fewer functional problems than rectal resection. However, one-third of the patients included in this strategy still report major LARS symptoms (39). Although there is to date insufficient evidence to draw firm conclusions about the oncological safety of this approach, this “watch-and-wait” strategy will be part of the future management of patients with rectal cancer.

Additionally, the strong correlation between major LARS and poor QoL may lead to a definitive stoma.

According to several studies, a definitive stoma will be required in approximately one patient out of 5 at 10 years due to perianastomotic septic complications, fecal incontinence and local recurrence (40,41). The responders with major LARS are managed to date according to our decisional algorithm (6). Thus, surgery and permanent stoma are indicated as a last resort, but only after ruling out a local recurrence. Most of

our RC survivors experienced genitourinary sequelae, a finding in keeping with other studies using validated scoring systems (7,18,32,42).

The major strength of this study is the consistency of the design. This was a high-resolution registry study based on a general population regardless of the medical center with an exhaustiveness close to 100 %. To avoid any potential bias on QoL or dysfunctions, only patients treated with curative intention and free of cancer disease were included. Moreover, a minimum 2-year follow-up period after stoma reversal was used as an inclusion criterion in order for patients to experience the potential functional improvements that may be observed in this period, as described by several authors (29,31). Another strength is that QoL, bowel and genito-urinary functions were studied with well-known and internationally validated questionnaires and scores. In a recent review, the EORTC questionnaires were shown to be the best health-related QoL tools for colorectal cancer patients (43).

However, there are also some limitations. First, this survey was cross-sectional and not longitudinal. Nevertheless, cross-sectional mapping of sequelae and QoL is a necessary step before making a longitudinal assessment on a large scale. However, our results were based on a population-based cancer registry and may be generalizable to all patients undergoing rectal cancer surgery. On the other hand, the longitudinal prospective studies with both pre- and post-treatment scores were derived from a “convenience cohort” of surviving rectal cancer treated in a single dedicated center (42,44,45). Recent findings highlight the difficulty of conducting these prospective studies, which were closed before reaching the target sample size.

Second, the high incidence of sexual dysfunction reported in our survey may be attributed not only to the use of validated instruments to assess dysfunction, but also to the inclusion of patients with probable pre-existing sexual dysfunction before the rectal cancer treatment. However, we have recently reported that de novo urinary dysfunction was observed in nearly 33% of patients and sexually dysfunction resulted in de novo cessation of sexual activity in 28% of men and 18% of women (7).

Third, the response rate was quite low, which might bias the results. This low response rate may be explained by both the strict inclusion criteria and the high number of validated questionnaires used. Moreover, questionnaires on sexuality may be very intrusive for patients, especially for women. Even if the comparison between responders and non-responders did not show any significant difference, we cannot definitively rule out that non-responders were more satisfied than responders. This may limit the determination of the effect of the treatment on genitor-urinary functioning. Regarding our responders, more than two thirds were male with a mean age of 61 years at surgery. According to statistics, 52% of elderly men may suffer from varying degrees of sexual dysfunction (46). This rate may partially explain our high incidence of sexual dysfunction. Moreover, rectal replacement with straight colorectal anastomosis was more frequent in the non-responders. However, it seems to date that the formation of a neo-rectal pouch (i.e., colonic J pouch or side-to-end anastomosis) provides advantages compared to a straight colorectal anastomosis only in the first year following surgery as suggested by both a recent meta-analysis and a prospective randomized controlled trial (47,48). In our survey, bowel continuity was restored in included patients for more than 24 months in order to avoid a bias. It was essential that responders and non-responders were comparable in our survey, according to predictive factors for a high LARS score (i.e., age, gender, tumor location, preoperative radiotherapy and TME compared with PME (34).

Finally, the QoL scores of RC patients were not compared with those of the general population in France. Unfortunately, our population-based study was not designed to evaluate the pre-therapeutic QOL or LARS score. Theoretically, normative data from the general population may be useful and can serve as proxy baseline data. To our knowledge, very few normative data about QOL or LARS score are available in the literature. According to a recent study, up to 19% of females and 10% of males without a rectal cancer experienced a major LARS score (49). In our population-based cancer registry, we reported LARS scores 2 to 4 times higher than those reported in the general population. In the future, it will be relevant to explore bowel function and QoL using validated instruments in the French population.

In summary, the results of this survey suggest that severe bowel dysfunction occurs in 40% of RC survivors. Despite a high prevalence of sexual dysfunction, poor QoL was mainly correlated with the severity of bowel dysfunction. Although these findings should be interpreted with caution because of several limitations, it is important to inform patients about the potential functional outcome of their surgery in terms of QoL and oncological prognosis.

## **ACKNOWLEDGEMENTS**

We would like to thank the following: Therese Juul (Aarhus University Hospital, Department of Surgery, Aarhus, Denmark) for her help and authorization to use a French version of the LARS score.

**Competing interests:** The authors declare no competing interests.

**Ethics approval:** this study was conducted according to the terms of the Declaration of Helsinki, approved by the local ethics committee (ID-RCB: 2017-A02645-48) and registered at ClinicalTrials.gov (ID: NCT03459235).

## List of abbreviations

C30 = Core 30

CR 29 = Colo Rectal 29

EORTC = European Organization for Treatment and Research of Cancer

GRECCAR = French Research Group for Rectal Cancer Surgery

FSFI = Female Sexual Function Index

IIEF 5 = Index of Erectile Function questionnaire 5

IPSS = International Prostate Symptom Score

LARS = Low Anterior Resection Syndrome

PME = Partial Mesorectal Excision

QLQ = Quality of Life Questionnaire

QoL = Quality of Life

RC = Rectal Cancer

SPS = Sphincter-preserving surgery

TME = Total Mesorectal Excision

USP = Urinary Symptom Profile




## **References:**

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. *European Journal of Cancer*. apr 2013;49(6):1374-403.
2. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017: Colorectal Cancer Statistics, 2017. *CA: A Cancer Journal for Clinicians*. 6 may 2017;67(3):177-93.
3. Lakkis Z, Manceau G, Bridoux V, Brouquet A, Kirzin S, Maggiori L, et al. Management of rectal cancer: the 2016 French guidelines. *Colorectal Disease*. feb 2017;19(2):115-22.
4. Rullier E, Laurent C, Bretagnol F, Rullier A, Vendrely V, Zerbib F. Sphincter-saving resection for all rectal carcinomas: the end of the 2-cm distal rule. *Ann Surg*. mar 2005;241(3):465-9.
5. Alves A. [Recommendations for clinical practice. Therapeutic choices for rectal cancer. How can we reduce therapeutic sequelae and preserve quality of life?]. *Gastroenterol Clin Biol*. jan 2007;31 Spec No 1:1S52-62, 1S95-97.
6. Sarcher T, Dupont B, Alves A, Menahem B. Anterior resection syndrome: What should we tell practitioners and patients in 2018? *Journal of Visceral Surgery*. oct 2018;155(5):383-91.
7. Abdelli A, Tillou X, Alves A, Menahem B. Genito-urinary sequelae after carcinological rectal resection: What to tell patients in 2017. *Journal of Visceral Surgery*. apr 2017;154(2):93-104.
8. Wiltink LM, Marijnen CAM, Meershoek-Klein Kranenbarg E, van de Velde CJH, Nout RA. A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial. *Acta Oncologica*. 2 apr 2016;55(4):502-8.
9. Krouse RS, Wendel CS, Garcia DO, Grant M, Temple LKF, Going SB, et al. Physical activity, bowel function, and quality of life among rectal cancer survivors. *Quality of Life Research*. nov 2017;26(11):3131-42.
10. Giandomenico F, Gavaruzzi T, Lotto L, Del Bianco P, Barina A, Perin A, et al. Quality of life after surgery for rectal cancer: a systematic review of comparisons with the general population. *Expert Review of Gastroenterology & Hepatology*. 2 sept 2015;9(9):1227-42.
11. Lai X, Wong FKY, Ching SSY. Review of bowel dysfunction of rectal cancer patients during the first five years after sphincter-preserving surgery: A population in need of nursing attention. *European Journal of Oncology Nursing*. oct 2013;17(5):681-92.
12. Bryant CL, Lunniss PJ, Knowles CH, Thaha MA, Chan CL. Anterior resection syndrome. *The Lancet Oncology*. sept 2012;13(9):e403-8.
13. Emmertsen KJ, Laurberg S, the Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer: Quality of life after sphincter-preserving resection for rectal cancer. *British Journal of Surgery*. sept 2013;100(10):1377-87.
14. Chapman SJ, Bolton WS, Corrigan N, Young N, Jayne DG. A Cross-Sectional Review of Reporting Variation in Postoperative Bowel Dysfunction After Rectal Cancer Surgery: *Diseases of the Colon & Rectum*. feb 2017;60(2):240-7.
15. Emmertsen KJ, Laurberg S. Low Anterior Resection Syndrome Score: Development and Validation of a Symptom-Based Scoring System for Bowel Dysfunction After Low Anterior Resection for Rectal Cancer. *Annals of Surgery*. may 2012;255(5):922-8.
16. Chen TY-T, Emmertsen KJ, Laurberg S. What Are the Best Questionnaires To Capture Anorectal Function After Surgery in Rectal Cancer? *Current Colorectal Cancer Reports*. feb 2015;11(1):37-43.

17. Chen TY-T, Emmertsen KJ, Laurberg S. Bowel dysfunction after rectal cancer treatment: a study comparing the specialist's versus patient's perspective. *BMJ Open*. jan 2014;4(1):e003374.
18. Celentano V, Cohen R, Warusavitarne J, Faiz O, Chand M. Sexual dysfunction following rectal cancer surgery. *International Journal of Colorectal Disease*. nov 2017;32(11):1523-30.
19. Walming S, Asplund D, Block M, Bock D, Gonzalez E, Rosander C, et al. Patients with rectal cancer are satisfied with in-hospital communication despite insufficient information regarding treatment alternatives and potential side-effects. *Acta Oncologica*. 10 july 2018;1-7.
20. Sun V, Grant M, Wendel CS, McMullen CK, Bulkley JE, Herrinton LJ, et al. Sexual Function and Health-Related Quality of Life in Long-Term Rectal Cancer Survivors. *The Journal of Sexual Medicine*. july 2016;13(7):1071-9.
21. Wallner C, Lange MM, Bonsing BA, Maas CP, Wallace CN, Dabhoiwala NF, et al. Causes of Fecal and Urinary Incontinence After Total Mesorectal Excision for Rectal Cancer Based on Cadaveric Surgery: A Study From the Cooperative Clinical Investigators of the Dutch Total Mesorectal Excision Trial. *Journal of Clinical Oncology*. 20 sept 2008;26(27):4466-72.
22. Böhm G, Kirschner-Hermanns R, Decius A, Heussen N, Schumpelick V, Willis S. Anorectal, bladder, and sexual function in females following colorectal surgery for carcinoma. *International Journal of Colorectal Disease*. sept 2008;23(9):893-900.
23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 3 mar 1993;85(5):365-76.
24. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. *European Journal of Cancer*. nov 2009;45(17):3017-26.
25. Fayers P, Aaronson N, Bjordal K, et al. The EORTC QLQ-C30 scoring manual, 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
26. Juul T, Ahlberg M, Biondo S, Emmertsen KJ, Espin E, Jimenez LM, et al. International Validation of the Low Anterior Resection Syndrome Score: *Annals of Surgery*. apr 2014;259(4):728-34.
27. Haab F, Richard F, Amarenco G, Coloby P, Arnould B, Benmedjahed K, et al. Comprehensive Evaluation of Bladder and Urethral Dysfunction Symptoms: Development and Psychometric Validation of the Urinary Symptom Profile (USP) Questionnaire. *Urology*. apr 2008;71(4):646-56.
28. Rosen, C. Brown, J. Heiman, S. Leib R. The Female Sexual Function Index (FSFI): A Multidimensional Self-Report Instrument for the Assessment of Female Sexual Function. *Journal of Sex & Marital Therapy*. apr 2000;26(2):191-208.
29. Bregendahl S, Emmertsen KJ, Lous J, Laurberg S. Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study. *Colorectal Disease*. apr 2013;n/a-n/a.
30. Chen TY-T, Wiltink LM, Nout RA, Meershoek-Klein Kranenbarg E, Laurberg S, Marijnen CAM, et al. Bowel Function 14 Years After Preoperative Short-Course Radiotherapy and Total Mesorectal Excision for Rectal Cancer: Report of a Multicenter Randomized Trial. *Clinical Colorectal Cancer*. june 2015;14(2):106-14.
31. Juul T, Ahlberg M, Biondo S, Espin E, Jimenez LM, Matzel KE, et al. Low Anterior Resection Syndrome and Quality of Life: an International Multicenter Study. *Diseases of the Colon & Rectum*. may 2014;57(5):585-91.

32. Kauff DW, Lang H, Kneist W. Risk Factor Analysis for Newly Developed Urogenital Dysfunction after Total Mesorectal Excision and Impact of Pelvic Intraoperative Neuromonitoring—a Prospective 2-Year Follow-Up Study. *Journal of Gastrointestinal Surgery*. june 2017;21(6):1038-47.
33. Pieniowski EHA, Palmer GJ, Juul T, Lagergren P, Johar A, Emmertsen KJ, et al. Low Anterior Resection Syndrome and Quality of Life After Sphincter-Sparing Rectal Cancer Surgery: A Long-term Longitudinal Follow-up. *Diseases of the Colon & Rectum*. jan 2019;62(1):14-20.
34. Battersby NJ, Bouliotis G, Emmertsen KJ, Juul T, Glynne-Jones R, Branagan G, et al. Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score. *Gut*. 23 jan 2017;gutjnl-2016-312695.
35. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 1 oct 2018;29(Supplement\_4):iv263-iv263.
36. Dolet N, Bouvier V, Eid Y, Thobie A, Boyer A, Haffreingue A, et al. Influence of social deprivation and remoteness on the likelihood of sphincter amputation for rectal cancer: a high-resolution population-based study. *International Journal of Colorectal Disease*. mar 2019;1.
37. Fink C, Diener MK, Bruckner T, Müller G, Paulsen L, Keller M, et al. Impact of preoperative patient education on prevention of postoperative complications after major visceral surgery: study protocol for a randomized controlled trial (PEDUCAT trial). *Trials*. 2013;14(1):271.
38. Ward S, Donovan H, Gunnarsdottir S, Serlin RC, Shapiro GR, Hughes S. A randomized trial of a representational intervention to decrease cancer pain (RIDCancerPain). *Health Psychology*. jan 2008;27(1):59-67.
39. Hupkens BJP, Martens MH, Stoot JH, Berbee M, Melenhorst J, Beets-Tan RG, et al. Quality of Life in Rectal Cancer Patients After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection – A Matched-Controlled Study. *Diseases of the Colon & Rectum*. oct 2017;60(10):1032-40.
40. Dinnewitzer A, Jäger T, Nawara C, Buchner S, Wolfgang H, Öfner D. Cumulative Incidence of Permanent Stoma After Sphincter Preserving Low Anterior Resection of Mid and Low Rectal Cancer: *Diseases of the Colon & Rectum*. oct 2013;56(10):1134-42.
41. Celerier B, Denost Q, Van Geluwe B, Pontallier A, Rullier E. The risk of definitive stoma formation at 10 years after low and ultralow anterior resection for rectal cancer. *Colorectal Disease*. jan 2016;18(1):59-66.
42. Adam J-P, Denost Q, Capdepon M, van Geluwe B, Rullier E. Prospective and Longitudinal Study of Urogenital Dysfunction After Proctectomy for Rectal Cancer: *Diseases of the Colon & Rectum*. sept 2016;59(9):822-30.
43. Wong CKH, Chen J, Yu CLY, Sham M, Lam CLK. Systematic review recommends the European Organization for Research and Treatment of Cancer colorectal cancer-specific module for measuring quality of life in colorectal cancer patients. *Journal of Clinical Epidemiology*. mar 2015;68(3):266-78.
44. Attaallah W, Ertekin SC, Yegen C. Prospective study of sexual dysfunction after proctectomy for rectal cancer. *Asian Journal of Surgery*. sept 2018;41(5):454-61.
45. Dulskas A, Samalavicius NE. A prospective study of sexual and urinary function before and after total mesorectal excision. *International Journal of Colorectal Disease*. june 2016;31(6):1125-30.
46. Chen L, Shi G, Huang D, Li Y, Ma C, Shi M, et al. Male sexual dysfunction: A review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention. *Biomedicine & Pharmacotherapy*. apr 2019;112:108585.
47. Hüttner FJ, Tenckhoff S, Jensen K, Uhlmann L, Kulu Y, Büchler MW, et al. Meta-analysis of reconstruction techniques after low anterior resection for rectal cancer. *British Journal of Surgery*. june 2015;102(7):735-45.

48. Marti WR, Curti G, Wehrli H, Grieder F, Graf M, Gloor B, et al. Clinical Outcome After Rectal Replacement With Side-to-End, Colon-J-Pouch, or Straight Colorectal Anastomosis Following Total Mesorectal Excision: A Swiss Prospective, Randomized, Multicenter Trial (SAKK 40/04). *Annals of Surgery*. sept 2018;1.
49. Juul T, Elfeki H, Christensen P, Laurberg S, Emmertsen KJ, Bager P. Normative Data for the Low Anterior Resection Syndrome Score (LARS Score): *Annals of Surgery*. mar 2018;1.



**Figure 1 - Flow Diagram of the study population**

	Responders N= 92 [%]	Non-responders N= 111 [%]	P Value
<u>Age at surgery (mean. (SD))</u>	60.7 years (11.3)	62.5 years (8.2)	0.23
<u>Age at test (mean. (SD))</u>	67.2 years (10.2)	69.0 years (7.8)	0.16
<u>Sex</u>			
<i>Male</i>	64 [69.6]	70 [63.1]	0.33
<i>Female</i>	28 [30.4]	41 [36.9]	
<u>Tumor location</u>			
<i>High</i>	31 [33.7]	35 [31.5]	0.95
<i>Mid</i>	45 [49.0]	56 [50.5]	
<i>Low</i>	16 [17.3]	20 [18.0]	
<u>Pathological T-staging</u>			
<i>pT0 – pT2</i>	54 [58.7]	67 [60.4]	0.81
<i>pT3 – pT4</i>	38 [41.3]	44 [39.6]	
<u>Pathological N-staging</u>			
<i>pN0</i>	63 [68.5]	86 [77.5]	0.15
<i>pN1-2</i>	29 [31.5]	25 [22.5]	
<u>Pathological TNM staging</u>			
<i>Stage 1</i>	43 [46.7]	58 [52.3]	0.35
<i>Stage 2</i>	20 [21.7]	28 [25.2]	
<i>Stage 3</i>	29 [31.5]	25 [22.5]	
<i>Stage 4</i>	0	0	
<u>Type of surgery</u>			
<i>TME</i>	62 [67.4]	76 [68.5]	0.87
<i>PME</i>	30 [32.6]	35 [31.5]	
<u>Neo-adjuvant therapy</u>			
<i>Chemoradiation</i>	46 [50.0]	56 [50.5]	0.95
<i>Short-course radiotherapy</i>	0	0	
<i>None</i>	46 [50.0]	55 [49.5]	
<u>Surgical approach</u>			
<i>Open</i>	62 [67.4]	57 [51.3]	0.10
<i>Laparoscopy</i>	22 [23.9]	41 [36.9]	
<i>Conversion in open surgery</i>	7 [7.6]	12 [10.8]	
<i>Robotic</i>	1 [1.1]	1 [0.9]	
<u>Intersphincteric resection</u>	27 [29.3]	21 [18.9]	0.08
<u>Anastomosis construction</u>			
<i>Straight anastomosis (end-to-end)</i>	36 [39.0]	61 [54.9]	0.06
Colonic Reservoir {			
<i>Side-to-end anastomosis</i>	44 [48.0]	36 [32.5]	
<i>Colonic J-pouch</i>	12 [13.0]	14 [12.6]	
<u>Anastomosis type</u>			
<i>Handsewn CAA</i>	22 [23.9]	22 [19.8]	0.48
<i>Stapled CRA</i>	70 [76.1]	89 [80.2]	
<u>Stoma type</u>			
<i>Temporary ostomy</i>	53 [57.6]	72 [64.9]	0.29
<i>None</i>	39 [42.4]	34 [35.1]	
<u>Adjuvant treatment</u>			
<i>none</i>	59 [64.1]	84 [75.7]	0.20
<i>Chemotherapy</i>	31 [33.7]	25 [22.5]	
<i>Chemo-radiotherapy</i>	2 [2.2]	2 [1.8]	
<u>Time since surgery (mean. (SD))</u>	6.5 years (3.9)	6.5 years (2.2)	0.89

CAA = Coloanal anastomosis, CRA = Colorectal anastomosis

**Table 1 – Comparison between responders and non-responders patients according to their characteristics**

Overall population	No LARS (0-20) [%]	Minor LARS (21-29) [%]	Major LARS (30-42) [%]	P value	Missing data [%]	Total [%]
<u>Whole population</u>	31 [33.7]	22 [23.9]	38 [41.3]	NA	1 [1.1]	92 [100]
<u>Sex</u>						
Male	22 [34.4]	14 [21.9]	28 [43.7]	0.71	0 [0]	64 [69.6]
Female	9 [32.1]	8 [28.6]	10 [35.7]		1 [3.6]	28 [30.4]
<u>Mesorectal excision</u>						
TME	14 [22.6]	17 [27.4]	30 [48.4]	0.006	1 [1.6]	62 [67.4]
PME	17 [27.4]	5 [16.7]	8 [26.6]		0 [0]	30 [32.6]
<u>Chemoradiation</u>						
Chemoradiation	10 [21.7]	8 [17.4]	28 [60.9]	<0.001	0 [0]	46 [50.0]
No Chemoradiation	21 [45.7]	14 [30.4]	10 [21.7]		1 [2.2]	46 [50.0]
<u>Anastomosis construction</u>						
Straight anastomosis	13 [36.1]	10 [27.8]	13 [36.1]	0.65	0 [0]	36 [39.1]
Colonic reservoir	18 [32.2]	12 [21.4]	25 [44.6]		1 [1.8]	56 [60.9]

NA: Not Applicable

**Table 2 – Results of bowel function (LARS score) for responder patients who underwent curative rectal resection**

<b>IPSS score</b>	Mild (1-7) [%]	Moderate (21-29) [%]	Severe (30-42) [%]	P value	Missing data [%]	Total [%]
Male population	46 [71.8]	15 [23.4]	1 [1.6]	NA	2 [3.2]	64 [100]
<u>Mesorectal excision</u>						
TME	28 [68.3]	10 [24.5]	1 [2.4]	0.68	2 [4.8]	41 [64]
PME	18 [78.3]	5 [21.7]	0 [0]		0 [0]	23 [36]
<u>Chemoradiation</u>						
Chemoradiation	25 [73.5]	7 [20.1]	1 [2.9]	0.56	1 [1.6]	34 [53.1]
No Chemoradiation	21 [70.0]	8 [26.7]	0 [0]		1 [1.6]	30 [46.9]
<u>Anastomosis construction</u>						
Straight anastomosis	23 [76.7]	6 [20.0]	0 [0]	0.66	1 [3.3]	30 [46.9]
Colonic reservoir	23 [71.9]	9 [28.1]	1 [3.1]		1 [3.1]	34 [53.1]

**Table 3.A – IPSS score**

<b>USP score</b>	Stress urinary incontinence Mean score (SD)	Overactive Bladder Mean score (SD)	Low stream Mean score (SD)	Total score Mean score (SD)	Missing data [%]	Total [%]
Female population	0.86 (1.6)	4.2 (3.4)	0.3 (0.7)	5.0 (4.6)	0 [0]	28 [100]
<u>Mesorectal excision</u>						
TME	0.9 (1.8)	4.1 (3.7)	0.4 (0.8)	5 (5.1)	0 [0]	21 [75.0]
PME	0.7 (1.1)	4.4 (2.4)	0.1 (0.4)	5.1 (3.1)		7 [25.0]
P value	0.79	0.83	0.46	0.95		
<u>Chemoradiation</u>						
Chemoradiation	0.9 (1.7)	5.0 (3.5)	0.3 (0.6)	5.6 (4.9)	0 [0]	16 [57.1]
No Chemoradiation	0.8 (1.6)	3.1 (3.2)	0.3 (0.9)	4.3 (4.3)		12 [42.9]
P value	0.95	0.15	0.94	0.49		
<u>Anastomosis construction</u>						
Straight anastomosis	0.2 (0.4)	3.7 (1.6)	0.2 (0.4)	3.8 (1.8)	0 [0]	6 [21.4]
Colonic reservoir	1 (1.8)	4.3 (2.6)	0.4 (0.8)	5.4 (5.1)		22 [78.6]
P value	0.25	0.69	0.56	0.48		

Abbreviations: NA = Not Applicable

**Table 3.B – USP score**

**Table 3 – Results of urinary function (IPSS score for men and USP score for women) for responder patients who underwent curative rectal resection**



<b><u>IIEF score</u></b>	Severe erectile dysf. (5-10) [%]	Moderate erectile dysf. (11-15) [%]	Mild erectile dysf. (16-20) [%]	No erectile dysf. (21-25) [%]	NI  (1-4) [%]	P value	Missing data [%]	Total [%]
<b><u>Male population</u></b>	13 [20.3]	8 [12.5]	8 [12.5]	6 [9.4]	25 [39.0]	NA	4 [6.3]	64 [100]
<b><u>Mesorectal excision</u></b>								
TME	10 [24.3]	5 [12.2]	4 [9.7]	4 [9.7]	16 [39.0]	0.80	2 [4.8]	41 [64.0]
PME	3 [13.0]	3 [13.0]	4 [17.4]	2 [8.7]	9 [39.2]		2 [8.7]	23 [36.0]
<b><u>Chemoradiation</u></b>								
Chemoradiation	5 [16.6]	4 [13.3]	2 [6.7]	3 [10.0]	14 [46.7]	0.59	2 [6.7]	30 [46.9]
No Chemoradiation	8 [23.5]	4 [11.8]	6 [17.7]	3 [8.8]	11 [32.3]		2 [5.9]	34 [53.1]
<b><u>Anastomosis construction</u></b>								
Straight anastomosis	5 [16.6]	5 [16.6]	4 [13.3]	4 [13.3]	9 [30.2]	0.52	3 [10.0]	30 [46.9]
Colonic reservoir	8 [23.5]	3 [8.8]	4 [11.8]	2 [5.9]	16 [47.1]		1 [2.9]	34 [53.1]

**Table 4.A – IIEF score in men**

<b><u>FSFI score</u></b>	FSFI	Desire	Arousal	Lubrication	orgasm	Satisfaction	Pain	Total [%]
Female population	12.4 (12.0)	2.5 (1.2)	2.0 (2.0)	2.2 (2.5)	2.3 (2.5)	2.1 (0.8)	2 (2.5)	28 [100]
Missing data [%]	4 [14]	4 [14]	4 [14]	3 [11]	3 [11]	8 [29]	3 [11]	NA
<b><u>Mesorectal excision</u></b>								
TME	13.5 (13.1)	2.4 (1.3)	1.8 (2.2)	2.2 (2.7)	2.2 (2.7)	3.6 (2.3)	1.9 (2.6)	17 [70.8]
PME	16 (9.6)	2.8 (0.9)	2.3 (1.8)	2.3 (2.0)	2.5 (2.0)	3.7 (1.9)	2.3 (2.1)	7 [29.2]
P value	0.65	0.45	0.60	0.91	0.81	0.91	0.67	
<b><u>Chemoradiation</u></b>								
Chemoradiation	13.5 (13.6)	2.6 (1.2)	1.9 (1.9)	2.3 (2.4)	2.3 (2.4)	3.9 (2.1)	2.2 (2.5)	9 [37.5]
No Chemoradiation	14.7 (11.4)	2.5 (1.3)	2.0 (2.3)	2.1 (2.7)	2.1 (2.7)	3.3 (2.2)	1.7 (2.5)	15 [62.5]
P value	0.82	0.86	0.90	0.82	0.86	0.51	0.61	
<b><u>Anastomosis construction</u></b>								
Straight anastomosis	13.9 (10.3)	2.6 (1.0)	1.3 (1.6)	2.6 (2.8)	2.3 (2.3)	3.5 (2.4)	2.0 (2.7)	5 [20.8]
Colonic reservoir	14.3 (12.7)	2.5 (1.3)	2.1 (2.1)	2.1 (2.5)	2.2 (2.6)	3.7 (2.1)	2.0 (2.5)	19 [79.2]
P value	0.95	0.97	0.47	0.72	0.95	0.89	1	

Abbreviations: dysf. = dysfunction; NA = Not Applicable, NI = Not Interpretable

**Table 4.B – FSFI mean scores in women (standard deviation)**

**Table 4 – Results of sexual function (IIEF score for men and FSFI score for women) for responder patients who underwent curative rectal resection**

**Table 5 – Results of simple and multiple linear regression (using backward selection) showing global quality of life score based on functional sequelae scores in men and women**

	Men				Women			
	Simple linear regression		Multiple linear regression		Simple linear regression		Multiple linear regression	
	Coefficient estimate	P Value	Coefficient estimate	P Value	Coefficient estimate	P Value	Coefficient estimate	P Value
Age	0.14	0.62	-	-	0.42	0.18	0.57	0.03
Bowel function	-0.39	0.04	-0.39	0.04	-1.09	0.0006	-1.22	0.0003
Urinary function	-0.84	0.05	-	-	-0.51	0.57	-	-
Sexual function	0.42	0.17	-	-	0.44	0.24	-	-

Overall population	Function score (SD)						Symptom score (SD)									Missing data [%]	Total [%]
	Global health status / QoL	Physical func.	Role func.	Emotional func.	Cognitive func.	Social func.	Fatigue	Nausea/vomiting	Pain	Dyspnea	Insomnia	Appetite loss	Constipation	Diarrhea	Fin. problems		
Whole population [%]	71.0 [19.2]	88.9 [15.8]	91.2 [18.0]	82.1 [20.1]	85.5 [17.1]	82.6 [24.5]	23.2 [21.2]	1.8 [8.0]	13.4 [21.3]	12.7 [19.7]	26.0 [31.0]	4.4 [13.3]	20.0 [29.5]	26.4 [28.8]	7.0 [19.0]	2 [2.2]	92 [100]
<b>Sex</b>																	
Male	69.5 (18.9)	88.8 (16.3)	90.7 (19.1)	84 (18.7)	84.6 (17.6)	82.5 (22)	22.8 (20.7)	1.3 (6.1)	13.3 (21.7)	15.1 (21.4)	23.4 (30.0)	3.1 (11.5)	19.0 (27.9)	27.0 (27.8)	7.9 (20.5)	2 [2.2]	92 [100]
Female	74.7 (19.9)	89 (15)	92.3 (15.4)	77.8 (22.9)	87.6 (15.7)	82.7 (29.8)	24.2 (22.8)	3.2 (11.6)	13.7 (20.8)	7.1 (13.9)	32.1 (32.7)	7.1 (16.6)	22.2 (33.3)	24.7 (31.5)	4.9 (15.2)		
P value	0.25	0.95	0.71	0.18	0.44	0.97	0.77	0.31	0.93	0.07	0.22	0.18	0.64	0.72	0.50		
<b>Mesorectal excision</b>																	
TME	70.8 (20.2)	89.9 (12.5)	91.8 (16.3)	81.0 (21.3)	85.2 (18.3)	77.8 (26.5)	25.1 (21.4)	2.7 (9.7)	14.5 (22.7)	13.4 (20.4)	26.2 (30.5)	3.8 (10.6)	19.1 (28.2)	29.5 (28)	5.6 (15.2)	2 [2.2]	92 [100]
PME	71.4 (17.6)	86.8 (21.2)	90.0 (21.3)	84.5 (17.6)	86.1 (14.6)	92.2 (16.2)	19.2 (20.8)	0 (0)	11.1 (18.2)	11.1 (18.2)	25.6 (32.4)	5.6 (17.7)	21.8 (32.5)	20.0 (29.8)	10.0 (25.0)		
P value	0.90	0.39	0.66	0.45	0.82	0.008	0.22	0.13	0.48	0.60	0.93	0.55	0.69	0.14	0.30		
<b>Chemoradiation</b>																	
No chemotherapy	73.9 (19.2)	88.5 (17.7)	92.8 (18.1)	84.6 (15.9)	85.9 (14.5)	87.8 (21.7)	19.0 (19.3)	1.8 (7.2)	12.7 (21.7)	13.8 (19.3)	26.8 (30.3)	4.3 (13.3)	21.5 (31.9)	18.8 (26.9)	7.4 (21.2)	2 [2.2]	92 [100]
Chemoradiation	68.0 (19)	89.3 (13.9)	89.6 (17.9)	79.6 (23.5)	85.2 (19.5)	77.4 (26.1)	27.3 (22.4)	1.9 (9.0)	14.1 (21)	11.6 (20.1)	25.2 (31.9)	4.3 (13.3)	18.5 (27.1)	34.0 (28.9)	6.7 (16.8)		
P value	0.15	0.82	0.41	0.24	0.85	0.04	0.06	0.96	0.75	0.60	0.80	1.0	0.64	<b>0.01</b>	0.85		
<b>Anast. construction</b>																	
Straight anast.	71.9 (18.0)	87.0 (21)	91.4 (19.5)	83.1 (21.6)	84.7 (18.4)	84.8 (20.8)	22.5 (22.1)	1.4 (6.2)	12.5 (21.6)	16.7 (20.3)	25.9 (32.0)	6.5 (17.5)	24.0 (32.5)	26.8 (30.7)	7.6 (18.2)	2 [2.2]	92 [100]
Colonic reservoir	70.5 (20.0)	90.0 (11.4)	91.0 (17.1)	81.5 (19.3)	86.0 (16.3)	81.2 (26.7)	23.6 (20.8)	2.1 (9.1)	14.0 (21.3)	10.1 (19.0)	26.0 (30.6)	3.0 (9.6)	17.3 (27.3)	26.0 (27.7)	6.7 (19.7)		
P value	0.73	0.37	0.93	0.71	0.72	0.51	0.81	0.69	0.75	0.12	0.98	0.22	0.29	0.90	0.82		

Abbreviations: anast = Anastomosis; Fin = Financial; Func. = function; QoL = Quality of Life; NA = Not Applicable; SD = Standard deviation

**Table 6 – Results of Health-related Quality of Life (EORTC QLQ-C30 mean scores in study groups (standard deviation)) for responder patients who underwent curative rectal resection**

Overall pop.	Functional scales (SD)				Symptom scales (SD)																	Missing data [%]	Total [%]
	Body image	Anxiety	Weight	Sexual interest	Urinary freq.	Blood and mucus in stools	Stool freq.	Urinary inc.	Dysuria	Abdom. pain	Buttock pain	Bloating	Dry mouth	Hair loss	Taste	Flat.	Faecal Inc.	Sore skin	Emb.	Imp. (men) N = 64	Dysp. (women) N=28		
Whole pop. [%]	85.8 [21.3]	74.6 [29.0]	85.5 [24.4]	65.0 [30.9]	31.0 [22.5]	2.4 [7.6]	31.7 [26.3]	6.2 [13.0]	1.4 [6.8]	14.9 [22.3]	7.6 [18.6]	22.8 [27.5]	15.2 [22.9]	3.3 [9.9]	5.4 [16.6]	53.1 [15.0]	18.7 [25.5]	12.5 [25.3]	17 [27.1]	50.3 [41.2]	28.6 [39.8]	2 [2.2]	92 [100]
<b>Sex</b>																							
Male	85.1 (19.0)	72.4 (28.8)	83.9 (23.0)	66.1 (30.4)	33.6 (21.3)	3.38 (9.0)	31.1 (27.0)	5.2 (12.2)	2.1 (8.1)	15.1 (22.9)	7.3 (20.1)	20.8 (26.2)	14.6 (22.1)	2.6 (9.0)	5.8 (18.4)	52.3 (15.4)	20.9 (25.4)	11.5 (24.6)	16.4 (27.2)	NA	NA	2 [2.2]	92 [100]
Female	87.3 (26.0)	79.8 (29.2)	89.3 (27.3)	62.1 (33.0)	25 (24.2)	0 (0)	33.3 (25.0)	8.3 (14.7)	0 (0)	14.3 (21.1)	8.3 (14.7)	27.4 (30.2)	16.7 (24.8)	4.8 (11.9)	4.8 (11.9)	54.8 (14.2)	13.3 (25.5)	14.7 (27.4)	18.7 (27.4)	NA	NA		
P value	0.66	0.26	0.33	0.61	0.09	0.05	0.72	0.29	0.18	0.87	0.81	0.30	0.69	0.34	0.80	0.48	0.22	0.60	0.73	NA	NA		
<b>Mes. excision</b>																							
TME	82.3 (23.0)	72.6 (29.9)	82.8 (24.7)	61.1 (32.9)	32.8 (23.4)	2.7 (8.6)	37.2 (25.8)	5.9 (12.8)	1.6 (7.2)	17.2 (23.9)	9.1 (20.2)	24.2 (29.1)	13.4 (20.4)	3.2 (9.9)	6.5 (17.9)	56.2 (14.2)	23.8 (27.5)	15.8 (26.3)	19.6 (28.3)	57.3 (41.1)	26.7 (42.2)	2 [2.2]	92 [100]
PME	93.1 (15.0)	78.9 (27.0)	91.1 (23.0)	72.6 (25.7)	27.2 (20.3)	1.7 (5.1)	20.8 (24.3)	6.7 (13.6)	1.1 (6.1)	10 (17.8)	4.4 (14.5)	20 (24.1)	18.9 (27.2)	3.3 (10.2)	3.3 (13.4)	46.7 (14.8)	8.3 (17.3)	6.0 (22.3)	11.9 (24.4)	36.7 (38.8)	33.3 (36.5)		
P value	0.02	0.33	0.13	0.11	0.27	0.55	0.007	0.80	0.74	0.15	0.26	0.50	0.29	0.96	0.40	0.004	0.008	0.10	0.22	0.07	0.74		
<b>CRad</b>																							
No CRad	92.4 (14.3)	78.3 (23.5)	87.7 (22.6)	72.2 (26.5)	33.7 (23.7)	1.8 (6.3)	18.7 (20.1)	7.2 (13.9)	0.7 (4.9)	14.5 (20.7)	3.6 (12.6)	19.6 (24.9)	18.8 (26.9)	2.9 (9.5)	2.9 (11.8)	48.2 (15.0)	9.8 (17.1)	2.4 (8.8)	7.3 (17.5)	42.0 (39.9)	17.9 (29.2)	2 [2.2]	92 [100]
CRad	79.5 (24.8)	71.0 (33.4)	83.3 (26.1)	57.5 (33.7)	28.3 (21.0)	2.9 (8.8)	44.2 (25.7)	5.1 (12.1)	2.2 (8.3)	15.2 (24.0)	11.6 (22.5)	26.1 (29.7)	11.6 (17.5)	3.6 (10.5)	8.0 (20.1)	58.0 (13.5)	27.1 (29.3)	22.2 (31.8)	26.4 (31.3)	57.3 (41.7)	45.8 (50.2)		
P value	0.003	0.23	0.40	0.03	0.25	0.50	<0.001	0.43	0.31	0.88	0.04	0.26	0.13	0.73	0.14	0.001	0.001	<0.001	0.001	0.16	0.12		
<b>Anast. Const.</b>																							
Straight anast.	88.3 (20.2)	74.1 (32.0)	85.2 (28.1)	66.7 (26.4)	29.2 (21.6)	2.3 (7.1)	29.8 (29.1)	4.6 (11.7)	1.9 (7.8)	11.1 (19.5)	6.5 (17.5)	23.1 (27.4)	17.6 (25.8)	3.7 (10.6)	4.6 (14.1)	50.9 (14.9)	12.1 (18.3)	14.1 (27.7)	19.2 (28.9)	41.7 (39.2)	41.7 (41.9)	2 [2.2]	92 [100]
Colonic reservoir	84.2 (22.0)	75 (27.2)	85.7 (21.9)	63.9 (33.9)	32.1 (23.1)	2.4 (8.1)	33.0 (24.6)	7.1 (13.8)	1.2 (6.2)	17.3 (23.8)	8.3 (19.3)	22.6 (27.8)	13.7 (20.9)	3.0 (9.6)	6.0 (18.1)	54.5 (15.1)	22.9 (28.7)	11.3 (23.9)	15.7 (26.1)	58.1 (42.1)	25.5 (40.0)		
P value	0.39	0.88	0.92	0.70	0.54	0.97	0.59	0.37	0.65	0.20	0.64	0.93	0.43	0.73	0.71	0.27	0.06	0.62	0.57	0.13	0.48		

Abbreviations: abdom. = abdominal; anast. = anastomosis; Const. = Construction; CRad = Chemoradiation; Dysp. =Dyspareunia; Emb. = Embarrassment; Flat. = flatulence; freq. = frequency; imp. = Impotence; inc. = incontinence; Pop. =Population; Mes. = mesorectal; NA = Not Applicable; SD = Standard deviation

**Table 7 – Results of Health-related Quality of Life (EORTC QLQ-Colorectal Cancer Module (CR29) mean scores in study groups (standard deviation) for responder patients who underwent curative rectal resection**